Ultragenyx Pharmaceutical Inc - Company Profile
Powered by 
All the sales intelligence you need on Ultragenyx Pharmaceutical Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ultragenyx Pharmaceutical Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ultragenyx Pharmaceutical Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Ultragenyx Pharmaceutical Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20230348906A1 | Application | Dux4 inhibitors and methods of use thereof | C12N15/113; A61K47/543; A61K47/6849; A61P21/00 | November 02, 2023 |
| EP3906066B1 | Grant | Constructions de thérapie génique pour le traitement de la maladie de wilson | C12N2750/14143; C12N9/6421; C12N15/86; A61K48/0058; C12N2750/14141; A61K48/005; A61P43/00 | November 01, 2023 |
| EP4269579A2 | Application | Constructions de thérapie génique pour le traitement de la maladie de wilson | C12N2750/14143; C12N9/6421; C12N15/86; A61K48/0058; C12N2750/14141; A61K48/005; A61P43/00 | November 01, 2023 |
| WO2023168202A3 | Application | Certain dux4 inhibitors and methods of use thereof | C12N15/113; C12N2310/14; C12N2310/315; C12N2310/3231; C12N2310/344 | October 26, 2023 |
| US11795473B2 | Grant | Use of tonicifying agents to enhance recombinant adeno-associated virus yield | C12N15/86; C12N2750/14152; C12N7/00 | October 24, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer